Ann: New mimotope cancer vaccine results published, page-2

Here we go folks, GO PD1-Vaxx !!!!!

Add this little beauty to HER-Vaxx and CF33 and as CEO Leslie Chongs states: "IMU is truly a multi-asset biopharmaceutical company."

SYDNEY, Australia, 28 May 2020: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced that its preclinical research related to its mimotope vaccines targeting immune checkpoint inhibitors has been accepted and published in the prestigious journal Frontiers in Immunology [1].

The ground-breaking research from Vienna, conducted under the leadership of Imugene SAB member Professor Dr Ursula Wiedermann with Dr Joshua Tobias as lead author, has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform, generate antibodies that bind specifically to immune cells expressing the PD1 biomarker.

The naturally produced antibodies block a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells, as shown in animal models of breast cancer.

Imugene MD & CEO Leslie Chong said “Development of this new immunotherapy expands our pipeline and further transforms Imugene into a multi-asset biopharmaceutical company.” The concept of teaching and inducing the body to generate its own antibodies targeting PD1 expressing cells represents a paradigm shift in oncology, and is the first journal report of treating cancer by this method. The publication is a detailed study of the mechanism of action of active immunisation targeting immune checkpoint regulator PD1.

The results validate and support the B cell “epitope” contained in Imugene’s PD1-Vaxx, scheduled to commence a Phase 1 trial in 2020.Imugene’s PD1-Vaxx is a B-cell cancer immunotherapy designed to treat tumors such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are